Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. Assess long-term safety of oral apremilast in psoriasis patients. Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluati...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American Academy of Dermatology Vol. 77; no. 2; pp. 310 - 317.e1
Main Authors:	Crowley, Jeffrey, Thaçi, Diamant, Joly, Pascal, Peris, Ketty, Papp, Kim A., Goncalves, Joana, Day, Robert M., Chen, Rongdean, Shah, Kamal, Ferrándiz, Carlos, Cather, Jennifer C.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.08.2017 Elsevier
Subjects:	Adult Anti-Inflammatory Agents, Non-Steroidal - adverse effects apremilast Cardiovascular Diseases - epidemiology clinical trial Depression - epidemiology Dermatology Diarrhea - chemically induced ESTEEM Female Headache - chemically induced Human health and pathology Humans Immunology Immunotherapy Incidence Life Sciences Male Middle Aged Nasopharyngitis - chemically induced Nausea - chemically induced Neoplasms - epidemiology phosphodiesterase 4 inhibitor psoriasis Psoriasis - drug therapy psoriatic arthritis Respiratory Tract Infections - chemically induced Rhumatology and musculoskeletal system safety Santé publique et épidémiologie Suicide, Attempted - statistics & numerical data Tension-Type Headache - chemically induced Thalidomide - adverse effects Thalidomide - analogs & derivatives Time Factors clinical trial ESTEEM GI AE EAIR psoriasis safety PDE4 phosphodiesterase 4 inhibitor psoriatic arthritis apremilast TB Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis tuberculosis adverse event gastrointestinal exposure-adjusted incidence rate phosphodiesterase 4
ISSN:	0190-9622, 1097-6787, 1097-6787
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!